Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | Using MatchMiner to improve clinical trial enrolment

Harry Klein • 10 Apr 2022
AACR 2022
General

Harry Klein, PhD, Dana Farber Cancer Institute, Boston, MA, explains how the MatchMiner platform from Dana-Farber Cancer Institute hopes to improve clinical trial enrolment. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

More from Harry Klein

MatchMiner: A new method of matching patients to precision medicine trials
1:29
MatchMiner: A new method of matching patients to precision medicine trials
Harry Klein • 10 Apr 2022

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals